



## Neuromonitoring au cours de la chirurgie cardiaque pédiatrique sous CEC.



**Pierre BOURGOIN, Anesthésiste  
Réanimateur,  
CLUB ECMO PEDIATRIQUE**

Fédération Cardiologie Pédiatrique et Congénitale  
Nantes, France

Actualisation 09/01/2026: DIU Anesthésie Réanimation des  
Cardiopathies Congénitales


# Plan

- Introduction: conséquences neurologiques de la CEC
- Débit Sanguin cérébral, estimation par la NIRS
- Autorégulation cérébrale pendant la CEC
  - Théorie
  - Mesure non invasive, Cox
  - Résultats préliminaires en pédiatrie
- Autres éléments du neuromonitoring per CEC
- Conclusion


# Plan

- **Introduction: conséquences neurologiques de la CEC**
- Débit Sanguin cérébral
- Autorégulation cérébrale pendant la CEC
  - Théorie
  - Mesure non invasive, Cox
  - Preuve de concept chez l'adulte
  - Résultats préliminaires en pédiatrie
- Autres éléments du neuromonitoring per CEC
- Conclusion

# Neurodevelopmental outcomes in children w/ CHD





# Does the anesthesiologist play any role?




# > TND après chirurgie cardiaque néonatale

## Perioperative Factors Associated with 2-Year Neurodevelopmental Outcome in Neonates Undergoing Surgery with Cardiac Disease: A Single-Center Cohort Study

Research | Published: 31 May 2025





Specific domain				
Communication	69	45±16	36.5	20 (29.8%)
Global motor	69	49±13	36	8 (11.8%)
Fine motor	69	51±10	36.4	6 (8.7%)
Problem solving	69	47±10	32.9	12 (17.4%)
Personal-social	69	46±11	35.6	16 (23.2%)
ASQ-total	69	238±47		





# Cerebral tissue oxygenation index and lactate at 24 hours postoperative predict survival and neurodevelopmental outcome after neonatal cardiac surgery

Safwat A. Aly, MD, MSc<sup>1</sup> | David Zurakowski, PhD<sup>2</sup> | Penny Glass, PhD<sup>3</sup> |  
Kami Skurow-Todd, MSN<sup>4</sup> | Richard A. Jonas, MD<sup>5</sup> | Mary T. Donofrio, MD<sup>4</sup>



# Optimizing Neurodevelopmental Outcomes in neonates and children with Congenital heart diseases



**30-50% New diagnosed WMI**

**Perioperative Hypoxia**

**Abrupt changes in CBF**

# MRI assessment of Neurologic injury after CHD Surgery

## Microembols, Bleeds:


- Fréquents,
- Quantifiables (MRI injury Score)
- Association pronostique?

## Lésions périventriculaires:

- Nouveau-né,
- Analogie preterm
- Liés aux modifications de CBF
- Immaturité BBB
- WMInjury
- Association pronostique possible

## Stroke:

- Rares,
- Embols, hémorragies
- Non dépistables en per op sauf massifs
- Association pronostique?





*Guo et Al, Neuroimage 2019*

## Watersheed infarcts:

- Liés à modification CBF prolongée
- Dépistables


Multimodal  
**NeuroMonitoring**  
during and After  
Neonatal **Cardiac**  
Surgery




Perioperative  
WMI suggests  
Abrupt  
variations of CBF

WMI and not  
Stroke are  
associated with  
late outcome



**CENTRAL ILLUSTRATION** The Effect of Peri-Operative Brain Injury on Motor Outcome at 30 Months of Age



*Peyvandi S et al JACC 2018*  
*Peyvandi S et al JACC 2024*




Multimodal  
**NeuroMonitoring**  
during and After  
Neonatal Cardiac  
Surgery




Challenges:

- Volume de priming: masse sanguine
  - Hypothermie
  - Cardioplégie
  - pH vs  $\alpha$ -stat
- Perfusion cérébrale sélective
  - Variations intercentres




Chris Barnard Division of  
Cardiothoracic Surgery

# Analyse exploratoire: Analyse en composante principale (PCA)



Réduit le nombre de dimensions dans les grands jeux de données, en composantes principales (=nouvelles variables ou Axes principaux)



	Component 1		
	Contribution 20.9147%		
	contrib.	coord.	cos2
DURINGCPB_Dose_LLA_right	20.5452	0.903562	0.816425
DURINGCPB_TICRltLLA_period_right	13.1551	0.723021	0.52276
MaxLac_J0	12.0788	0.692812	0.479989
SaO2 [%]	10.5521	-0.647549	0.419319
DURINGCPB_LLA_right	8.51834	0.581809	0.338502
Temp_minimale	7.32453	-0.539502	0.291062
Hct [%]	6.36324	-0.502854	0.252863
DURINGCPB_TICRgtULA_period_right	5.9779	-0.487391	0.23755
DeltaCRE_MAX	5.01925	0.446604	0.199455
DURINGCPB_dose_ULA_right	3.78541	-0.387846	0.150425
LOS_Hospital	2.63027	0.323298	0.104522
Poids	2.57721	0.32002	0.102413
PaO2 [mmHg]	0.503567	0.141459	0.0200108
COx_r_ptime_above_0.3_during	0.422529	-0.129578	0.0167905
SvO2 [%]	0.275654	-0.104661	0.0109539
gestational_age	0.121804	0.0605077	0.00484284

# Plan

- Introduction: conséquences neurologiques de la CEC
- **Débit Sanguin cérébral, NIRS**
- Autorégulation cérébrale pendant la CEC
  - Théorie
  - Mesure non invasive, Cox
  - Preuve de concept chez l'adulte
  - Résultats préliminaires en pédiatrie
- Autres éléments du neuromonitoring per CEC
- Conclusion


# Débit Sanguin Cérébral

## Débit Sanguin Cérébral (DSC)

- Seule source d'O<sub>2</sub>
- 15 à 30% de Q<sub>c</sub> (50 ml/100g/min)

→  $DSC = PPC / RVC$

→  $PPC = PAM - (PVC + PIC)$



## REVIEW ARTICLE

### **Cerebral blood flow in the neonate**

Laszlo Vutskits<sup>1,2</sup>

1 Department of Anesthesiology, Pharmacology and Intensive Care, University Hospital of Geneva, Geneva, Switzerland

2 Department of Fundamental Neuroscience, Geneva University Medical School, Geneva, Switzerland

Normal values of CBF in healthy volunteers: 40-50 ml/ 100g.min<sup>-1</sup>

Irreversible brain damage < 10 ml/100g.min<sup>-1</sup>

How to monitor CBF in the Bedside?


→ TCD

→ NIRS



How to ensure adequate CBF during CPB?

→ Optimal MAP? Optimal Blood flow?



# Le (la) NIRS, de quoi parle-t-on?





**Loi de Beer Lambert:** on mesure la concentration d'une substance selon son degré d'absorption de la lumière



Limites: Hb < 6g/dL; Ht > 60%  
Melanin





NN: Volume env. 1.5 cm<sup>3</sup>



Comp. A: 25%  
Comp. V: 75%

- ✓ Oxygen consumption is 3.5 mL of oxygen/100 g tissue/1 min
- ✓ Extraction augmente si CBF chute (CMRO<sub>2</sub>= constant)
- ✓ CBF chute de 50%: dette en O<sub>2</sub>

$$rSO_2 = \frac{HbO_2}{Hb}$$



# NIRS: surrogate of DO<sub>2</sub>



Pediatric Cardiac  
Surgery Annual



## Noninvasive Assessment of Cardiac Output

George M. Hoffman, Nancy S. Ghanayem, and James S. Tweddell



Improved outcome from shock depends on early detection and correction of circulatory abnormalities. Global cardiac output and oxygen delivery must be adequate and distributed appropriately to meet metabolic demands to prevent the development of multiple organ system dysfunction, prolonged morbidity, and death. Circulatory assessment using standard monitors gives incomplete and sometimes misleading information. This article focuses on the available and emerging technologies that emphasize assessment of blood flow and regional tissue oxygenation.

Semin Thorac Cardiovasc Surg Pediatr Card Surg Ann 8:12-21 © 2005 Elsevier Inc. All rights reserved.



**KEYWORDS:** SVO<sub>2</sub> (mixed venous saturation), cardiac output, hemodynamic monitoring, near-infrared spectroscopy, shock





**Figure 11** The two-site NIRS model shows good prediction of  $SvO_2$  for within-patient trends.





**Figure 10** A linear combination of cerebral and somatic  $rSO_2$  provided a better approximation of  $SvO_2$  than either alone.






**FIGURE 2.** (A) Regional cerebral oxygen saturation during resuscitation by blood infusion, (B) RrSO<sub>2</sub> during resuscitation by blood infusion, (C) CrSO<sub>2</sub> during blood pressure management using phenylephrine infusion, and (D) RrSO<sub>2</sub> during blood pressure management using phenylephrine infusion. Data clusters reflect the five repeat measurements performed for each subject during each procedure step. The line represents the mean percent CrSO<sub>2</sub> or RrSO<sub>2</sub> across all measurements, with 95% CIs. Statistical significance relative to baseline (pre-hemorrhage) is denoted as \* representing P < .0001. Abbreviations: CrSO<sub>2</sub>, regional cerebral oxygen saturation; RrSO<sub>2</sub>, regional cerebral oxygen saturation.






Continuous recording of hemodynamic variables and cerebral/somatic NIRS  
n=6, 3 animals initiated by hypoventilation, and 3 animals begun by hyperventilation

Time 0 (60 min)	→	Hypoventilation + CO <sub>2</sub> (15 min)	→	Hyperventilation (15 min)
Baseline gasometry, NIRS, baseline echo-Doppler		Gasometry, baseline echo-Doppler at the tail end of hypoventilation	Clearance period (60 min)	Gasometry, baseline echo-Doppler at the tail end of hyperventilation



**Figure 3.** Changes after hyper- and hypoventilation in **A**, jugular vein blood flow; **B**, fractional cerebral tissue oxygen extraction (FTOE); **C**, cerebral oxygen saturation (rSaO<sub>2</sub>); and **D**, somatic rSaO<sub>2</sub>. Data are reported as means ± SD. \*P < 0.05 compared to basal (t-test).


# NIRS: surrogate of CBF



The correlation between brain near-infrared spectroscopy and cerebral blood flow in piglets with intracranial hypertension


*Alosh et al, J Appl Physiol 1985*

→ à  $P_{aCO_2}$  constante,  $SaO_2$  constante,  
 $Q_c$  constant et  $[Hb]$  constant, le volume total  
D'Hb ne peut varier que par variation du DSC



## Quantitative measurements of cerebral blood flow with near-infrared spectroscopy

$$\text{CBF}_0 = \frac{1}{\rho_b} \frac{\mathcal{F}^{(c)} \text{CBV}_0^{(c)}}{t^{(c)}} = \frac{1}{\rho_b} \frac{[\text{HbT}]_0}{\text{ctHb}} \frac{\mathcal{F}^{(c)} \text{CBV}_0^{(c)}}{\text{CBV}_0 t^{(c)}}$$




# Continuous Time-Domain Analysis of Cerebrovascular Autoregulation Using Near-Infrared Spectroscopy *Stroke* 2007

Ken M. Brady, MD, Jennifer K. Lee, MD, Kathleen K. Kibler, BS, Piotr Smielewski, PhD, Marek Czosnyka, PhD, R. Blaine Easley, MD, Raymond C. Koehler, PhD, and Donald H. Shaffner, MD




*Department of Anesthesiology and Critical Care Medicine (K.M.B., J.K.L., K.K.K., R.B.E., R.C.K., D.H.S.), Johns Hopkins University School of Medicine, Baltimore, Md; and the Department of Academic Neurosurgery (P.S., M.C.), Addenbrooke's Hospital, Cambridge, UK.*



- ✓ 6 piglets
- ✓ Laser Doppler: Gold Standard measure



- NIRS may be used as a surrogate of CBF to determine LLA ( Static measurement here)
- The study highlights the association of MAP and NIRS value!



# Cerebral Oxygen Saturation-Time Threshold for Hypoxic-Ischemic Injury in Piglets



cRSO<sub>2</sub> restauré qqsoit la durée d'HIE

Modèle HIE-Reperfusion.  
Modèle: cRSO<sub>2</sub> 35-40%




Figure 1. Cerebral O<sub>2</sub> saturation (ScO<sub>2</sub>) during the study in each group. Control group (◇-◇) received anesthesia without hypoxia-ischemia (H-I). Other groups experienced episodes of 1 h H-I (○-○), 2 h H-I (□-□), 3 h H-I (▲-▲), 4 h H-I (◆-◆), 6 h H-I (●-●), or 8 h H-I (■-■) while anesthetized. Time 0 is baseline. During H-I, ScO<sub>2</sub> was targeted to 35%. Reperfusion after H-I is indicated by the arrow. In the control group, arrow indicates recovery after discontinuing anesthesia. Values are mean ± SD, n = 4 to 8 in each group.

# Cerebral Oxygen Saturation-Time Threshold for Hypoxic-Ischemic Injury in Piglets




Figure 4. Electrocortical activity (ECA) during the study relative to baseline. ΔECA as measured by trough value on the cerebral function monitor in each group. Groups and symbols same as in Figure 1. Baseline is before H-I.

*Kurth D, Anest Analg 2009*




Figure 5. Electrocortical activity during reperfusion relative to baseline. ΔECA as measured by the peak and trough values on the cerebral function monitor (cfm) during reperfusion after varying duration of hypoxia-ischemia (H-I). The control group is indicated by 0 h of H-I. \* is  $P < 0.05$  vs control.

Fonction cérébrale (CFM-aEEG) en fonction du temps d'ischémie (cRSO<sub>2</sub> 35-40%)

Lésions neuronales critiques à H2

# Low-Flow Cardiopulmonary Bypass: Importance of Blood Pressure in Maintaining Cerebral Blood Flow

Robert E. Michler, MD, Aqeel A. Sandhu, MD, William L. Young, MD, and Arthur E. Schwartz, MD

Cardiac Transplantation Research Laboratory, Departments of Surgery and Anesthesia, Columbia University College of Physicians & Surgeons, and Cardiothoracic Surgery and Anesthesiology Services, Presbyterian Hospital in the City of New York, New York, New York




Table 1. Physiologic Variables Before and During Cardiopulmonary Bypass<sup>a</sup>

Variable	Before Bypass	Full-Flow CPB		Low-Flow CPB	
		High BP	Low BP	High BP	Low BP
CBF (mL · min <sup>-1</sup> · 100 g <sup>-1</sup> )	26.0 ± 3.1	27.6 ± 9.9	16.8 ± 3.7 <sup>b</sup>	34.0 ± 8.3	14.1 ± 3.7 <sup>b</sup>
A-VO <sub>2</sub> (mL/100 mL)	5.1 ± 1.7 <sup>b</sup>	2.5 ± 1.3	3.0 ± 1.8	2.2 ± 0.9	3.3 ± 0.5
CMRO <sub>2</sub> (mL · min <sup>-1</sup> · 100 g <sup>-1</sup> )	1.2 ± 0.4 <sup>b</sup>	0.68 ± 0.40	0.49 ± 0.25	0.70 ± 0.20	0.44 ± 0.20
MABP (mm Hg)	69 ± 13	61 ± 2	24 ± 3	62 ± 2	23 ± 3
Pump flow (L · min <sup>-1</sup> · m <sup>-2</sup> )	...	2.23 ± 0.06	2.23 ± 0.06	0.75	0.75
Temperature (°C)	35 ± 0.8	27.7 ± 0.4	27.7 ± 0.5	27.7 ± 0.5	27.8 ± 0.4
pCO <sub>2</sub> (mm Hg)	33 ± 4	34 ± 2	33 ± 2	36 ± 4	36 ± 3
pH	7.48 ± 0.03 <sup>c</sup>	7.42 ± 0.04	7.43 ± 0.07	7.41 ± 0.05	7.41 ± 0.04
pO <sub>2</sub> (mm Hg)	499 ± 31 <sup>d</sup>	377 ± 128	382 ± 115	431 ± 95	425 ± 112
Hematocrit	30 ± 3 <sup>b</sup>	16 ± 4	16 ± 4	16 ± 3	16 ± 4

<sup>a</sup> Values are mean ± standard deviation; arterial blood gas analyses were performed at 37°C. <sup>b</sup> *p* < 0.01 compared with others. <sup>c</sup> *p* < 0.05 compared with others. <sup>d</sup> *p* < 0.05 compared with full-flow high BP, full-flow low BP, low-flow low BP.

A-VO<sub>2</sub> = cerebral arteriovenous oxygen content difference; CPB = cardiopulmonary bypass; CBF = cerebral blood flow; CMRO<sub>2</sub> = cerebral oxygen metabolic rate; MABP = mean arterial blood pressure; pCO<sub>2</sub> = carbon dioxide tension; pO<sub>2</sub> = oxygen tension.

# Murkin Protocol 2008. NIRS-based Algorithm





# Rappel: Evaluation d'un dispositif de monitoring/ Outil diagnostic



- Déterminer une **valeur pronostique**
- Etude observationnelle prospective. Preuve de concept. En aveugle. Critère de jugement sensibles (marqueurs biologiques, imagerie).

- Déterminer un **impact dans la prise en charge**: l'outil modifie t il la pratique et de quelle manière?
- Etude observationnelle randomisée avec choix du critère de jugement principal sensible (exemple: modification de pratique, marqueurs biologiques)

- Prouver un **bénéfice clinique**
- Etude interventionnelle randomisée dont le bras interventionnel utilise l'outil (algorithme de prise en charge) et le groupe témoin est une pratique standard. Evaluation en aveugle du groupe de randomisation.



**Cerebral near-infrared spectroscopy (NIRS) for perioperative monitoring of brain oxygenation in children and adults (Review)**

Yu Y, Zhang K, Zhang L, Zong H, Meng L, Han R

Open Access

Research

**BMJ Open** Effects of cerebral near-infrared spectroscopy on the outcome of patients undergoing cardiac surgery: a systematic review of randomised trials

---

Giuseppe Filiberto Serraino, Gavin J Murphy

**Table 3** Summary of main findings of systematic review and GRADE assessment of trial results**Near-infrared spectroscopy algorithm compared with control (standard care) in cardiac surgery****Patient population: adult cardiac surgery; setting: tertiary cardiac centres****Intervention: near-infrared spectroscopy algorithms for personalised optimisation of cerebral oxygenation****Control: standard care**

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Participants (n) (studies)	Quality of the evidence (GRADE)
	Risk with control	Risk with NIRS			
Mortality	32 per 1000	25 per 1000 (10 to 63)	RR 0.76 (0.30 to 1.96)	608 (4 RCTs)	⊕⊕○○ Low
Red cell transfusion	504 per 1000	469 per 1000 (388 to 564)	RR 0.93 (0.77 to 1.12)	744 (4 RCTs)	⊕⊕○○ Low
Stroke	16 per 1000	17 per 1000 (6 to 46)	RR 1.08 (0.40 to 2.91)	1138 (7 RCTs)	⊕○○○ Very low
Myocardial infarction	29 per 1000	26 per 1000 (12 to 54)	RR 0.90 (0.43 to 1.89)	1038 (6 RCTs)	⊕○○○ Very low
Renal failure	71 per 1000	62 per 1000 (41 to 95)	RR 0.88 (0.58 to 1.34)	1043 (6 RCTs)	⊕○○○ Very low
Reoperation for bleeding	19 per 1000	21 per 1000 (8 to 56)	RR 1.11 (0.41 to 3.04)	744 (4 RCTs)	⊕○○○ Very low
ICU length of stay (ICU LOS)		The mean ICU LOS in the intervention group was 0 (0.44 lower to 0.44 higher).			⊕○○○ Very low
Hospital length of stay (H LOS)		The mean H LOS was 0.45 lower (0.9 lower to 0.01 higher).			⊕⊕○○ Low

\*The risk in the intervention group (and its 95% CIs) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

# Cerebral oxygen saturation and tissue hemoglobin concentration as predictive markers of early postoperative outcomes after pediatric cardiac surgery

Hamamatsu  
NIRO

Tomohiko Suemori<sup>1,2</sup>, Justin Skowno<sup>3,4</sup>, Steve Horton<sup>5,6</sup>, Stephen Bottrell<sup>5</sup>, Warwick Butt<sup>7,8</sup> & Andrew J. Davidson<sup>1,9,10</sup>



**Table 5** Cut-off values for postoperative TOI and Δ[HHb]

	Major morbidity				Mortality			
	Sensitivity	Specificity	PPV	NPV	Sensitivity	Specificity	PPV	NPV
TOI postop <40%	21	95	27	93	25	94	12	98
TOI postop <45%	27	91	22	93	33	90	10	98
TOI postop <50%	42	83	18	94	75	83	12	99
Δ[HHb] >10	27	91	21	93	41	86	8	98
Δ[HHb] >8	33	87	18	94	50	77	6	98
Δ[HHb] >6	52	78	18	95	50	71	5	98

TOI, tissue oxygenation index; Δ[HHb], amount change in deoxygenated hemoglobin; PPV, positive predictive value; NPV, negative predictive value.

# Perioperative Near-Infrared Spectroscopy Monitoring in Neonates With Congenital Heart Disease: Relationship of Cerebral Tissue Oxygenation Index Variability With Neurodevelopmental Outcome PCCM 2016

Michael C. Spaeder, MD<sup>1</sup>; Darren Klugman, MD<sup>2</sup>; Kami Skurow-Todd, MSN<sup>3</sup>; Penny Glass, PhD<sup>4</sup>; Richard A. Jonas, MD<sup>5</sup>; Mary T. Donofrio, MD<sup>3</sup>

**TABLE 2. Patient and Clinical Characteristics Stratified by Neurodevelopmental Outcome**

Characteristic	Normal Neurodevelopmental Outcome (n = 24) n (%)	Poor Neurodevelopmental Outcome (n = 20) n (%)	p
Age (d)	6 (IQR, 3–7)	6 (IQR, 4–9)	0.27
Weight (g)	3,482 (sd, 475)	3,320 (sd, 495)	0.14
Cardiopulmonary bypass time (min)	123 (IQR, 109–143)	116 (IQR, 106–125)	0.36
Underwent DHCA	24 (100%)	18 (90%)	0.20
DHCA time (min)	25 (IQR, 8–42)	45 (IQR, 39–50)	<b>0.01</b>
CHD classification			0.06
Class 1	12 (50%)	4 (20%)	
Class 2	2 (8%)	1 (5%)	
Class 3	0	0	
Class 4	10 (42%)	15 (75%)	
Single ventricle defects (class 3 and 4)	10 (42%)	15 (80%)	<b>0.03</b>
CHD with aortic obstruction (class 2 and 4)	12 (50%)	16 (80%)	<b>0.04</b>
Mean intraoperative cTOI	63 (sd, 7)	63 (sd, 9)	0.41
Nadir intraoperative cTOI	35 (sd, 14)	33 (sd, 16)	0.31
Intraoperative cTOI variability	2.7 (IQR, 2.2–3.5)	2.7 (IQR, 2.1–3.9)	0.99
Mean postoperative cTOI	56 (sd, 12)	55 (sd, 11)	0.32
Nadir postoperative cTOI	34 (sd, 16)	38 (sd, 11)	0.71
Postoperative cTOI variability	1.6 (IQR, 1.2–3)	1 (IQR, 0.8–1.7)	<b>0.01</b>

cTOI = cerebral tissue oxygenation index, CHD = congenital heart disease, DHCA = deep hypothermic circulatory arrest, IQR = interquartile range. Boldface values reflect significant results.



Review Article

# Near-Infrared Spectroscopy in Pediatric Congenital Heart Disease

Katherine L. Zaleski, MD<sup>1</sup>, Barry D. Kussman, MBCh, FFA(SA)

*Department of Anesthesiology, Perioperative, and Critical Care Medicine, Division of Cardiac Anesthesia,  
Boston Children's Hospital, Boston, MA*

## **NIRS en chirurgie cardiaque pédiatrique:**

- Un outil devenu incontournable
- Algorithme interventionnel « de bon sens »
- Association pronostique modeste
- Aucune étude rapportant la faisabilité d'intervention basées sur l'utilisation du NIRS
- Prédiction d'évènements neurologiques: bas débit (et non: stroke!)

## Cerebral Tissue Oxygen Saturation (ScO<sub>2</sub>)

- <60%
- Down-trending
- L-R difference > 10%\*
- Not increasing with cooling

Ensure secure airway and adequate oxygenation.

### Verify Monitoring Integrity

1. Confirm sensor placement – ensure adequate skin contact, limit ambient light.
2. Verify head position – place head midline, neck neutral, limit lateral rotation.
3. Confirm adequate signal quality.†

### Evaluate Cerebral DO<sub>2</sub>

#### Pre-CPB/Post-CPB/ICU/Cath Lab

1. ↑ FiO<sub>2</sub> if appropriate.
2. Exclude hypocapnia.
3. Optimize ABP and CO<sup>‡</sup>  
Consider fluid bolus, inotrope, vasopressor or vasodilator as appropriate
4. Correct anemia (acyanotic <30%, cyanotic <40%) – consider PRBC.

#### CPB

1. Exclude malposition of aortic + venous cannulae – discuss with surgeon.
2. Evaluate adequacy of CPB:
  - PaO<sub>2</sub>, SaO<sub>2</sub>, and/or SvO<sub>2</sub> low: ↑ FiO<sub>2</sub>, ↑ Q.
  - MAP or CPP low: ↑ Q, add vasopressor
  - Hb/Hct low: ultrafiltration, PRBC
3. PaCO<sub>2</sub> (at 37°C) low: pH stat strategy.

#### Special Considerations:

- During RCP → ↑ Q.
- During DHCA: ScO<sub>2</sub> < 45% - reperfuse if possible.

### Evaluate CMRO<sub>2</sub>

#### Pre-CPB/Post-CPB/ICU/Cath Lab

1. Increase depth of sedation/anesthesia.
2. Prevent hyperthermia.
3. Consider mild hypothermia.
4. Rule out and treat seizures.
5. Assess for and treat intracranial pathology.

#### CPB

1. Increase depth of anesthesia.
2. Cool further or consider increased duration of cooling.
3. Place ice on the head.
4. Prevent excessive warming at CPB end.

# Plan

- Introduction: conséquences neurologiques de la CEC
- Débit Sanguin cérébral
- **Autorégulation cérébrale pendant la CEC**
  - Théorie
  - Mesure non invasive, Cox
  - Résultats préliminaires en pédiatrie
- Autres éléments du neuromonitoring per CEC
- Conclusion


# Débit Sanguin Cérébral


## Débit Sanguin Cérébral (DSC)

- Seule source d'O<sub>2</sub>
- 15 à 30% de Q<sub>c</sub> (50 ml/100g/min)
- $DSC = PPC / RVC$

→  $PPC = PAM - (PVC + PIC)$


→ Sujet à une AUTOREGULATION








Remember your  
classics!

## Cerebral Autoregulation (CAR): classical view




-----  
Dotted  
line...effect of  
CAR  
disruption


# >Des travaux de Laassen à une conception dynamique de L'ARC




# > Conséquences cliniques ('*CAR disruption*')



*E. Vu et al, 2023*



# Comment estimer un statut d'ARC?





Mesurer la PAM

Estimer le DSC

- Laser Doppler
- PIC
- NIRS




Coefficient de Corrélation






Multimodal  
NeuroMonitoring  
during and After  
Neonatal Cardiac

# 'Frequency-based' analysis



Coefficient de Corrélacion: COx

Moving Correlation Factor  
(300sec/10sec)








*'Hybrid Model'*

**Static**

Vascular Diameter




**Dynamic**




Chronic or steady state  
changes in BP


Rapid changes in BP




# Best Fitting Curve



Multimodal  
NeuroMonitoring  
during and After  
Neonatal Cardiac  
Surgery




## 'CAR-derived metrics'




a




b



c




d



# Personalized Blood Pressure Management During Cardiac Surgery With Cerebral Autoregulation Monitoring: A Randomized Trial



Charles W. Hogue, MD,<sup>\*</sup> Charles H. Brown IV, MD, MPH,<sup>†</sup> Daijiro Hori, MD,<sup>‡</sup> Masa Ono, MD,<sup>§</sup> Yohei Nomura, MD,<sup>‡</sup> Lauren C. Balmert, PhD,<sup>||</sup> Nina Srdanovic, MS,<sup>||</sup> Jordan Grafman, PhD,<sup>||</sup> and Kenneth Brady, MD<sup>\*\*</sup> The Cerebral Autoregulation Study Group<sup>#</sup>




CLINICAL RESEARCH ARTICLE

Check for updates



# Clinical research study: cerebral autoregulation in neonates and infants undergoing open heart surgery: global patterns and derived cerebral hemodynamic metrics

Pierre Bourgoin<sup>1,2,3</sup>, Erta Beqiri<sup>4</sup>, Peter Smielewski<sup>4</sup>, Ariane De Windt<sup>3</sup>, Remi Bernardon<sup>3</sup>, Guillaume Emeriaud<sup>5</sup>, Ugo Gouedard<sup>3</sup>, Alban Baruteau<sup>6</sup>, Alexis Chenouard<sup>2</sup>, Nicolas Joram<sup>2</sup> and Pascal Amedro<sup>1,7</sup>


© The Author(s), under exclusive licence to the International Pediatric Research Foundation, Inc 2025



# > CAR-status recovery after CPB (1)



# CAR-status recovery after CPB (2)






## Body Perfusion (lactates)

	Coefficient	95% CI	p-value	Sig.
(Intercept)	4.09	[-1.874, 10.048]		
CPB duration	0.004	[-0.008, 0.017]	0.52	
RACHS-2 category	0.213	[-0.768, 1.192]	0.66	
Dose MAP < LLA	0.227	[0.081, 0.371]	0.003	**
AUC RSO2 < 60%	0.036	[-0.001, 0.073]	0.06	
Cardiac Index [l/min/m <sup>2</sup> ]	-1.302	[-3.478, 0.872]	0.23	


	24h max. Lactate	***CPB duration	**ACC duration	Cardiac index CPB	mean hematocrit CPB	mean SvO2 CPB	PaO2 CPB	PaCO2 CPB	minimal core temp.	Age at surgery	**AUC RSO2 < 60%	mean MAP	*MAPopt	ULA	*LLA	%time COx > 0.3	Dose MAP > ULA	***Dose MAP < LLA
24h max. Lactate	1.00	0.42	0.25	-0.34	-0.06	0.07	0.30	-0.11	-0.44	-0.03	0.26	0.13	0.26	0.29	0.25	0.02	-0.01	0.48
***CPB duration	0.42	1.00	0.69	-0.45	0.05	0.13	0.22	-0.14	-0.62	-0.20	0.42	0.13	0.15	0.02	0.08	-0.02	0.26	0.32
**ACC duration	0.25	0.69	1.00	-0.16		0.14	0.03	-0.05	-0.58	0.01	0.49	0.16	0.18	0.15	0.10	-0.09	0.06	0.04
Cardiac index CPB	-0.34	-0.45	-0.16	1.00	0.11	-0.15	-0.57	0.16	0.68	0.36	-0.15	-0.09	-0.15	-0.08	-0.11	-0.04	-0.03	-0.22
mean hematocrit CPB	-0.06	0.05		0.11	1.00	0.20	-0.02	-0.19	0.20	-0.04	0.01	0.04	-0.07	-0.27	-0.11	0.17	0.08	-0.17
mean SvO2 CPB	0.07	0.13	0.14	-0.15	0.20	1.00	0.31	-0.24	-0.10	-0.35	-0.11	0.07	-0.01	-0.15	-0.23	0.16	0.23	-0.27
PaO2 CPB	0.30	0.22	0.03	-0.57	-0.02	0.31	1.00	-0.27	-0.42	-0.24	-0.12	0.06	0.07	0.03	0.02	0.06	0.02	0.08
PaCO2 CPB	-0.11	-0.14	-0.05	0.16	-0.19	-0.24	-0.27	1.00	0.01	0.22	-0.01	0.03	0.08	0.11	0.02	-0.12	-0.11	-0.03
minimal core temp.	-0.44	-0.62	-0.58	0.68	0.20	-0.10	-0.42	0.01	1.00	0.22	-0.35	-0.08	-0.30	-0.22	-0.23	0.10	-0.11	-0.42
Age at surgery	-0.03	-0.20	0.01	0.36	-0.04	-0.35	-0.24	0.22	0.22	1.00	0.03	-0.04	0.23	0.31	0.20	-0.22	-0.13	0.15
**AUC RSO2 < 60%	0.26	0.42	0.49	-0.15	0.01	-0.11	-0.12	-0.01	-0.35	0.03	1.00	0.20	0.22	0.14	0.22	-0.07	-0.08	0.24
mean MAP	0.13	0.13	0.16	-0.09	0.04	0.07	0.06	0.03	-0.08	-0.04	0.20	1.00	0.43	0.45	0.30	0.01	0.10	0.17
*MAPopt	0.26	0.15	0.18	-0.15	-0.07	-0.01	0.07	0.08	-0.30	0.23	0.22	0.43	1.00	0.85	0.79	-0.15	-0.39	0.60
ULA	0.29	0.02	0.15	-0.08	-0.27	-0.15	0.03	0.11	-0.22	0.31	0.14	0.45	0.85	1.00	0.39	-0.32	-0.41	0.40
*LLA	0.25	0.08	0.10	-0.11	-0.11	-0.23	0.02	0.02	-0.23	0.20	0.22	0.30	0.79	0.39	1.00	-0.10	-0.25	0.70
%time COx > 0.3	0.02	-0.02	-0.09	-0.04	0.17	0.16	0.06	-0.12	0.10	-0.22	-0.07	0.01	-0.15	-0.32	-0.10	1.00	0.32	-0.05
Dose MAP > ULA	-0.01	0.26	0.06	-0.03	0.08	0.23	0.02	-0.11	-0.11	-0.13	-0.08	0.10	-0.39	-0.41	-0.25	0.32	1.00	-0.16
***Dose MAP < LLA	0.48	0.32	0.04	-0.22	-0.17	-0.27	0.08	-0.03	-0.42	0.15	0.24	0.17	0.60	0.40	0.70	-0.05	-0.16	1.00





**Body Perfusion (reins)**

	Coefficient	95% CI	p-value	Sig.
(Intercept)	0.56	[0.18, 0.94]		
CPB duration	0.003	[0.0002, 0.005]	0.03	*
RACHS-2 category	-0.015	[-0.18, 0.16]	0.86	
Dose MAP < LLA	0.032	[0.003, 0.06]	0.03	*
AUC RSO2 < 60%	0.0006	[-0.006, 0.008]	0.85	
Cardiac Index [l/min/m <sup>2</sup> ]	-0.06	[-0.54, 0.42]	0.78	



Multimodal  
NeuroMonitoring  
during and After  
Neonatal Cardiac  
Surgery



Et le cerveau?

Original Article

# Optimal brain perfusion pressure derived from the continuous monitoring of cerebral autoregulation status during neonatal heart surgery under cardiopulmonary bypass in relation to brain injury: An observational study

Pierre Bourgoin<sup>a,b,c,\*</sup>, Erta Beqiri<sup>d</sup>, Peter Smielewski<sup>d</sup>, Alexis Chenouard<sup>b</sup>, Aurélie Gaultier<sup>e</sup>, Flavie Sadones<sup>f</sup>, Ugo Gouedard<sup>c</sup>, Nicolas Joram<sup>b</sup>, Pascal Amedro<sup>a,g</sup>

<sup>a</sup>*IHU Liryc, Electrophysiology and Heart Modelling Institute, INSERM 1045, University of Bordeaux, Pessac, France*

<sup>b</sup>*Pediatric Intensive Care Unit, Nantes University Hospital, Nantes, France*



<sup>c</sup>*Department of Anesthesiology, Nantes University Hospital, Nantes, France*


<sup>d</sup>*Brain Physics Laboratory, Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom*

<sup>e</sup>*Department of Biostatistics, Nantes University, Nantes, France*


<sup>f</sup>*Department of Pediatric Radiology, Nantes University Hospital, Nantes, France*

<sup>g</sup>*Pediatric and Congenital Cardiology Department, M3C National Reference Center, Bordeaux University Hospital, Bordeaux, France*





	Total	No or 1 Minor lesion	Moderate or severe lesion
	(n = 38)	(n = 21)	(n = 17)
<b>White Mater Injury (WMI)</b>			
0: No WMI lesion	35 (92.11%)	21 (100.00%)	14 (82.35%)
1: Less than 3 lesions of less than 2 mm each or less than 5 mm diameter total lesion	0		
2: more than 3 WMI lesions OR one lesion > 2 mm, OR total diameter > 5mm	3 (7.89%)	0 (0.00%)	3 (17.65%)
3: severe: > 15 mm total diameter	0		
<b>Ischemic stroke</b>			
0 : No ischemic stroke	33 (86.84%)	20 (95.24%)	13 (76.47%)
1: less than 1/3 of an arterial territory OR ischemic zone less than 5mm	3 (7.89%)	1 (4.76%)	2 (11.76%)
2: 1/3 to 2/3 of an arterial territory OR ischemic zone diameter 6 to 15 mm	1 (2.63%)	0 (0.00%)	1 (5.88%)
3: > 2/3 of an arterial territory OR total ischemic zone > 15 mm	1 (2.63%)	0 (0.00%)	1 (5.88%)
<b>Intraparenchymal hemorrhagic (IPH) stroke</b>			
0: no IPH	38 (100.00%)	21 (100.00%)	17 (100.00%)
1 : IPH 1-5 mm diameter	0		
2 :IPH 6-15 mm diameter	0		
3 : IPH > 15 mm diameter	0		
<b>Intraparenchymal punctiform lesion (bleeds)</b>			
0: no bleed	8 (21.05%)	8 (38.10%)	0 (0.00%)
1: 1 to 3 punctiform lesions of < 2mm each	17 (44.74%)	12 (57.14%)	5 (29.41%)
2: 4 a 6 punctiform lesions of < 2 mm each	10 (26.32%)	0 (0.00%)	10 (52.94%)
3: > 6 lesions de < 2 mm each	3 (7.89%)	0 (0.00%)	3 (17.65%)
<b>Intraventricular hemorrhage (IVH)</b>			
0: no IVH	34 (89.47%)	20 (95.24%)	14 (82.35%)
1 :IVH < 6 mm diameter	3 (7.89%)	1 (4.76%)	2 (11.76%)
2: IVH-isolated OR total diameter 6 to 15 mm	1 (2.63%)	0 (0.00%)	1 (5.88%)
3: IVH and Intraventricular dilatation OR total diameter > 15 mm	0		
<b>Subdural Hemorrhage (SDH)</b>			
0: no SDH or isolated posterior SDH evocating perinatal SDH	33 (86.84%)	19 (90.48%)	14 (82.35%)
1: Minimal sus tentorial SDH	5 (13.16%)	2 (9.52%)	3 (17.65%)
2 : Spread to interhemispheric fissure in occipital aera	0		
3 : Larger hemorrhage, interhemispheric to parietal or frontal aera	0		
<b>Cerebral Venous Thrombosis (CVT)</b>			
0: No CVT	36 (94.74%)	21 (100.00%)	15 (88.24%)
1: CVT, one transverse sinus	2 (5.26%)	0 (0.00%)	2 (11.76%)
2 :CVT, bilateral	0		
3 :CVT, bilateral AND sagittal	0		



**Table 2**  
Hemodynamic and metrics derived from the monitoring of CAR during CPB according to post-operative MRI findings.

Variable	All patients (n = 38)	No or minor lesion (n = 21)	Moderate or severe lesion (n = 17)	p-Value
MAP, mean values (mmHg)	53.5 ± 8.3	53.6 ± 7.0	53.2 ± 10.2	0.91
%Time MAP < 40 mmHg (%)	14.8 [9.3–24.5]	13.2 [8.3–23.4]	14.9 [11.2–27]	0.80
cRSO <sub>2</sub> , mean values (%)	56.6 ± 9.7	55.8 ± 9.3	57.7 ± 10.7	0.59
Dose cRSO <sub>2</sub> < 60% (%*h)	13.3 [5.6–32.5]	14.6 [5.1–28.0]	10.9 [7.5–35.6]	0.39
Dose cRSO <sub>2</sub> < 50% (%*h)	2.6 [0.14–10.5]	2.4 [0.1–11.7]	2.9 [0.2–10.9]	0.92
Dose cRSO <sub>2</sub> < 40% (%*h)	0.4 [0.0–2.3]	3.3 [0.0–2.9]	0.2 [0.0–1.6]	0.90
Mean COx	0.38 ± 0.09	0.37 ± 0.08	0.41 ± 0.13	0.32
Dose COx > 0.3 (unit*h)	0.67 ± 0.31	0.62 ± 0.29	0.74 ± 0.35	0.28
MAPopt (mmHg)	49.9 [46–55.9]	49.7 [44.1–55.2]	50.1 [46.4–59.4]	0.74
LLA (mmHg)	40.8 [36.8–47.2]	39.6 [33.6–41.9]	46.1 [40.0–49.4]	0.09
ULA (mmHg)	59.5 [50.1–65.7]	60.8 [49.6–65.4]	58.1 [51.1–66.6]	0.92
%Time MAP > ULA (%)	37.5 [23.8–48.0]	38.8 [26.4–49.0]	35.8 [18.2–43.8]	0.77
Dose MAP > ULA (mmHg*h)	5.7 [2.4–9.7]	8.1 [2.6–11.0]	4.2 [2.5–8.1]	0.45
%Time MAP < LLA (%)	16.7 [8.3–29.0]	9.9 [6.9–18.5]	28.3 [17.1–32.9]	<b>0.039</b>
Dose ABP < LLA <sup>†</sup> (mmHg*h)	1.8 [0.7–5.9]	0.8 [0.5–3.6]	5.0 [1.5–7.0]	0.06

# Perspectives (1)



**Intégration d'un nouveau monitoring au bloc/ En réanimation**  
**-Etapas-**

Etapas	Exemple du monitoring de l'ARC
Faisabilité dans une population d'intérêt	 CEC néonatale : patient à risque de lésions neurologiques
Eléments de pertinence clinique, preuve de concept	 Détermination de pression de perfusion optimale, temps passé en dehors d la cible, lésions viibles en imagerie
Association à un élément du devenir	 Association à des marqueurs de la perfusion d'organes
Détermination de seuils critiques, valeur pronostique	 Nécessite un plus grand nombre de patient et un critère de jugement sensible. En cours.
Validation en cohorte externe	 En cours
Intégration dans un algorithme décisionnel	 En projet
Preuve de la supériorité du management grâce à l'outil	 A évaluer

# Plan

- Introduction: conséquences neurologiques de la CEC
- Débit Sanguin cérébral
- Autorégulation cérébrale pendant la CEC
  - Théorie
  - Mesure non invasive, Cox
  - Preuve de concept chez l'adulte
  - Résultats préliminaires en pédiatrie
- **Autres éléments du neuromonitoring per CEC**
- Conclusion

# Neuromonitoring Modalities in Pediatric Cardiac Anesthesia: A Review of the Literature

Elizabeth Finucane, DO<sup>1</sup>, Edmund Jooste, MBChB,  
Kelly A. Machovec, MD, MPH

*Duke University Medical Center, Durham, NC*

Table 1  
Summary of Advantages and Disadvantages of Each Neuromonitoring Modality, Including Recommendations for Use

Modality	Advantages	Disadvantages	Uses	Recommendations
TCD	<ul style="list-style-type: none"> <li>• Noninvasive</li> <li>• Inexpensive</li> </ul>	<ul style="list-style-type: none"> <li>• Variable anatomic window</li> <li>• Anterior fontanelle closes by 9-18 mo</li> <li>• Subjective results</li> <li>• User dependent</li> <li>• Does not indicate flow through smaller cerebral vessels</li> <li>• Dependent on adequate blood flow</li> </ul>	<ul style="list-style-type: none"> <li>• Cerebral blood flow measurement during low-flow CPB</li> <li>• CPB pump flow titration and pulsatility index</li> <li>• Cerebral emboli detection</li> </ul>	Use of > 1 neuromonitoring modality simultaneously
EEG	<ul style="list-style-type: none"> <li>• Noninvasive</li> </ul>	<ul style="list-style-type: none"> <li>• Cumbersome equipment</li> <li>• Expensive</li> <li>• Time consuming</li> <li>• Need trained technician</li> </ul>	<ul style="list-style-type: none"> <li>• Obtain preoperative neurologic status</li> <li>• Monitoring during DHCA</li> <li>• Prediction of postoperative seizures and monitor for seizures</li> </ul>	
NIRS	<ul style="list-style-type: none"> <li>• Noninvasive</li> <li>• Able to use throughout perioperative period</li> <li>• Real-time monitoring</li> <li>• More effective than TCD in low-flow states and DHCA</li> </ul>	<ul style="list-style-type: none"> <li>• Limited by location on forehead</li> <li>• Need baseline measurement</li> <li>• Interference by other substances (conjugated bilirubin, methylene blue)</li> <li>• Unreliable if hematocrit &gt;60%</li> </ul>	<ul style="list-style-type: none"> <li>• Monitoring of perfusion during low-flow states (eg, innominate artery cannulation, DHCA)</li> <li>• Adjustment of vasoactive medications, ventilator settings, and CPB indices in response to cerebral saturation changes</li> </ul>	

# **Novel cerebral physiologic monitoring to guide low-flow cerebral perfusion during neonatal aortic arch reconstruction**


Dean B. Andropoulos, MD<sup>a</sup>  
Stephen A. Stayer, MD<sup>a</sup>  
E. Dean McKenzie, MD<sup>b</sup>  
Charles D. Fraser, Jr, MD, FACS<sup>b</sup>

*JCTVS 2003*

# **Real-Time Continuous Neuromonitoring Combines Transcranial Cerebral Doppler with Near-Infrared Spectroscopy Cerebral Oxygen Saturation During Total Aortic Arch Replacement Procedure: A Pilot Study**

*ASAIO 2012*

XIAOHUA WANG,\* BINGYANG JI,† BAOHUI YANG,‡ GANG LIU,† NA MIAO,§ JING YANG,§ JINPING LIU,† AND CUN LONG†



« Bonne » corrélation  
rSO<sub>2</sub> VmMCA  
(r<sup>2</sup>= 0.22 Andropoulos et al.)

**Table 2. Perioperative Monitoring Parameters**

Variable	Pump Flow (ml/min)	Temperature (°C)	MAP (mm Hg)	VmMCA (cm/s)	rSO <sub>2</sub> (%)	SVO <sub>2</sub> (%)
Before incision		36.4 ± 0.7	80 ± 9.2	34.7 ± 14.2	68.8 ± 9.4	
10 min post-CPB	4240 ± 450	30.4 ± 2.4	55.4 ± 9.7	32.7 ± 11.6	63.4 ± 11.6	84.2 ± 5.4
10 min post-cross-clamp	4290 ± 440	26.3 ± 3.6	57.8 ± 11.2	28.9 ± 10.1	57.9 ± 9.8	89.7 ± 6.6
5 min post-ASCP	832 ± 189	21.8 ± 2.8	22 ± 7	15.3 ± 7.2*†	51.4 ± 7.8*	67.4 ± 7.9
10 min post-ASCP	807 ± 214	22.4 ± 2.3	24 ± 6	14.7 ± 6.4*†	52.7 ± 8.9*	61.5 ± 5.8
5 min after full flow	4350 ± 520	21.2 ± 3.1	61.7 ± 13.1	29.4 ± 9.8	55.3 ± 4.5	80.1 ± 9.3
10 min postrewarming	4340 ± 480	28.7 ± 3.9	59.4 ± 9.7	31.3 ± 12.7	54.1 ± 5.8	78.4 ± 7.9
10 min postresuscitation	4370 ± 540	29.7 ± 3.4	58.2 ± 10.2	32.3 ± 12.0	55.4 ± 8.6	77.2 ± 6.5
Postoff pump		36.8 ± 2.4	77.8 ± 14.1	32.7 ± 11.9	53.7 ± 9.1	

\*Compared with the induced,  $p < 0.05$ .

†Compared with post-off pump,  $p < 0.05$ .


ASCP, antegrade selective cerebral perfusion; CPB, cardiopulmonary bypass; rSO<sub>2</sub>, regional cerebral oxygen saturation; VmMCA, middle cerebral artery mean velocity; SVO<sub>2</sub>, venous oxygen saturation; MAP, mean arterial pressure.

# Patient management algorithm combining processed electroencephalographic monitoring with cerebral and somatic near-infrared spectroscopy: a case series



A Denault CJA 2019

- ✓ Adult patients during CPB
- ✓ PSI: Patient State Index (EMG artifacts)
- ✓ DSA: Density spectral array (=Processed EEG features)
- ✓ Arrows indicate state of suppression EEG




# Multimodal Neuromonitoring During Pediatric Cardiac Surgery

Jyrson Guilherme Klamt<sup>1</sup>, MD; Waynice Neiva de Paula Garcia<sup>1</sup>, MD; Mariana de Carvalho<sup>1</sup>, MD; Luis Vicente Garcia<sup>1</sup>, MD; Antonio Carlos Menardi<sup>2</sup>, MD




NICU-MIND QI Team



*Amplitude Integrated EEG*

## BACKGROUND PATTERNS

A characteristic aEEG strip is shown on the left, and a schematic view is shown on the right.




# Conclusion

✓ NIRS 1<sup>ère</sup> modalité d'estimation du DSC

En comprendre les limites:

Association pronostique modeste  
Algorithmes non évalués



✓ **DSC optimal = perfusion tissulaire optimale**

✓ Des stratégies de détermination de MAP opt sont à l'étude

✓ TCD: difficile, à associer au NIRS (cf présentation suivante)

✓ EEG: plutôt en post opératoire

# PH-STAT

VS

# $\alpha$ -STAT

PCO<sub>2</sub> corrigée à la température

Principe: ↓ du Débit Gaz Frais pendant l'hypothermie: PaCO<sub>2</sub> corrigée stable, PaCO<sub>2</sub> non corrigée ↑

CBF stable, Améliore DO<sub>2</sub> (shift de la courbe de dissociation de l'Hb vers la droite)

Améliore le cooling

« Perte d'autorégulation »



PCO<sub>2</sub> NON corrigée à la température

Principe: PaCO<sub>2</sub> non corrigée stable (PaCO<sub>2</sub> corrigée baisse)

CBF abaissé

« Autorégulation maintenue »  
(pas d'ajout de CO<sub>2</sub>)

Fonctions cellulaires préservées à pH alcalin.